NZ545917A - Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone - Google Patents

Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Info

Publication number
NZ545917A
NZ545917A NZ545917A NZ54591704A NZ545917A NZ 545917 A NZ545917 A NZ 545917A NZ 545917 A NZ545917 A NZ 545917A NZ 54591704 A NZ54591704 A NZ 54591704A NZ 545917 A NZ545917 A NZ 545917A
Authority
NZ
New Zealand
Prior art keywords
pyridin
methanone
peaks
chlorophenyl
triazol
Prior art date
Application number
NZ545917A
Other languages
English (en)
Inventor
Alfio Borghese
David Scott Coffey
Pamela Kaye Footman
Steven Wayne Pedersen
Susan Marie Reutzel-Edens
Shella Lenyonga Tameze
Carsten Weber
Carsten Timpe
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ545917A publication Critical patent/NZ545917A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ545917A 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone NZ545917A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (1)

Publication Number Publication Date
NZ545917A true NZ545917A (en) 2009-11-27

Family

ID=34549327

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ545917A NZ545917A (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
NZ580480A NZ580480A (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ580480A NZ580480A (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Country Status (28)

Country Link
US (1) US7381826B2 (cg-RX-API-DMAC10.html)
JP (1) JP4959336B2 (cg-RX-API-DMAC10.html)
KR (1) KR100848407B1 (cg-RX-API-DMAC10.html)
CN (1) CN1863791B (cg-RX-API-DMAC10.html)
AR (1) AR046131A1 (cg-RX-API-DMAC10.html)
AT (1) ATE462700T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004285855B8 (cg-RX-API-DMAC10.html)
BR (1) BRPI0415010B8 (cg-RX-API-DMAC10.html)
CA (1) CA2542140C (cg-RX-API-DMAC10.html)
CL (2) CL2009001311A1 (cg-RX-API-DMAC10.html)
CR (1) CR8353A (cg-RX-API-DMAC10.html)
DE (1) DE602004026333D1 (cg-RX-API-DMAC10.html)
DK (1) DK1675846T3 (cg-RX-API-DMAC10.html)
EA (1) EA008881B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP066517A (cg-RX-API-DMAC10.html)
ES (1) ES2340772T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20100207T1 (cg-RX-API-DMAC10.html)
IL (1) IL174926A0 (cg-RX-API-DMAC10.html)
MA (1) MA28329A1 (cg-RX-API-DMAC10.html)
MY (1) MY157375A (cg-RX-API-DMAC10.html)
NO (1) NO335090B1 (cg-RX-API-DMAC10.html)
NZ (2) NZ545917A (cg-RX-API-DMAC10.html)
PE (1) PE20050481A1 (cg-RX-API-DMAC10.html)
PT (1) PT1675846E (cg-RX-API-DMAC10.html)
TW (1) TW200524906A (cg-RX-API-DMAC10.html)
UA (1) UA82901C2 (cg-RX-API-DMAC10.html)
WO (1) WO2005042515A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200603234B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121610B1 (en) * 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
RU2770050C2 (ru) 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
IL281569B2 (en) 2018-09-28 2025-04-01 Vanda Pharmaceuticals Inc Use of tradipient in motion sickness
US20220096449A1 (en) 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant
WO2026152024A1 (en) 2025-01-09 2026-07-16 Vanda Pharmaceuticals Inc. Method of treating nausea and vomiting after glp-1r agonist administration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
DE60039616D1 (de) * 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
WO2001032656A1 (en) * 1999-10-29 2001-05-10 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Also Published As

Publication number Publication date
NZ580480A (en) 2010-02-26
CA2542140A1 (en) 2005-05-12
KR100848407B1 (ko) 2008-07-28
AR046131A1 (es) 2005-11-23
DE602004026333D1 (de) 2010-05-12
PT1675846E (pt) 2010-04-20
EA008881B1 (ru) 2007-08-31
US20070078166A1 (en) 2007-04-05
CL2009001310A1 (es) 2009-12-04
CN1863791B (zh) 2011-12-07
DK1675846T3 (da) 2010-05-31
BRPI0415010B8 (pt) 2021-05-25
AU2004285855A1 (en) 2005-05-12
NO20062371L (no) 2006-05-24
EA200600829A1 (ru) 2006-08-25
AU2004285855B8 (en) 2011-04-28
NO335090B1 (no) 2014-09-08
JP4959336B2 (ja) 2012-06-20
CL2009001311A1 (es) 2009-10-02
TW200524906A (en) 2005-08-01
ZA200603234B (en) 2007-07-25
IL174926A0 (en) 2006-08-20
BRPI0415010B1 (pt) 2019-07-09
WO2005042515A1 (en) 2005-05-12
PE20050481A1 (es) 2005-09-20
ATE462700T1 (de) 2010-04-15
US7381826B2 (en) 2008-06-03
HRP20100207T1 (hr) 2010-05-31
CN1863791A (zh) 2006-11-15
ES2340772T3 (es) 2010-06-09
JP2007509143A (ja) 2007-04-12
ECSP066517A (es) 2006-10-10
BRPI0415010A8 (pt) 2018-05-08
CR8353A (es) 2006-06-06
MA28329A1 (fr) 2006-12-01
MY157375A (en) 2016-06-15
UA82901C2 (en) 2008-05-26
KR20060061388A (ko) 2006-06-07
BRPI0415010A (pt) 2006-11-07
AU2004285855B2 (en) 2010-12-23
CA2542140C (en) 2012-05-29

Similar Documents

Publication Publication Date Title
CA2542140C (en) Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
EP3580220B1 (en) Aminotriazolopyridines as kinase inhibitors
JP6254075B2 (ja) カリウムチャネル遮断剤としてのアミン誘導体
JP5608162B2 (ja) 疾患を治療するのに有用なトリアゾール誘導体
EP2121610B1 (en) Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
NZ547164A (en) Derivatives of n-[phenyl(piperidine-2-yl)methyl]benzamide, preparation and therapeutic use thereof
US6534505B2 (en) Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same
JP6619503B2 (ja) Cgrp受容体アンタゴニスト
AU2024242411A1 (en) Crystalline forms of an azetidine parp1 inhibitor
US5866565A (en) Substituted-4-amino-3-pyridinols
IL297206A (en) Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1-yl)phenyl] -6-oxo- 1,6-dihydropyrimidine - 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02 6] octadeca- 1(18), 2(6), 4, 14, 16- pentaene -8-one
EP1675846B1 (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h- [1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CN1980666B (zh) 制备阿扎那韦硫酸氢盐的方法和新的形式
EP3481801B1 (en) Indoline derivatives and method for using and producing the same
MXPA06004444A (en) Novel crystalline forms of {2-[1-(3, 5-bis-trifluoromethylbenzyl) -5-pyridin-4-yl -1h-[1, 2, 3]triazol -4-yl]- pyridin-3-yl}- (2-chlorophenyl) -methanone
HK40064417A (en) Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate
HK40064417B (en) Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate
TW201514162A (zh) 作爲鉀離子通道抑制劑之呔

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed